• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Spirometrix lands $17m Series C for breath-based diagnostic device

Spirometrix lands $17m Series C for breath-based diagnostic device

July 1, 2016 By Brad Perriello

SpirometrixSpirometrix said yesterday that it raised $17.4 million in the 1st tranche of its Series C round for the breath-based diagnostic device it’s developing for asthma patients.

Shanghai Fosun Pharmaceutical (SHA:600196) led the round, joined by prior investors NGK Spark Plug, South Valley Angels, Iconical, Ohio Innovation Foundation and Carmen Innovation, Spirometrix said.

The Fenom Pro device is designed to measure the fraction of exhaled nitric oxide (FeNO) in exhaled breath, a biomarker for asthma. The Pleasanton, Calif.-based company, founded in 2011, said the device is based on sensor technology developed at the Ohio State University by Prabir Dutta. Spirometrix said its system also tracks data from other devices and monitors local pollen counts, pollution indices and air quality, looking to recognize and manage patterns.

Spirometrix said it’s raised a total of $29 million since its inception.

“We are extremely pleased not only to have Shanghai Fosun Pharmaceutical as a major financial and strategic partner in China, but also that our Series A and B lead investors have participated in this third round of financing,” CEO Dean Zikria said in prepared remarks. “This Series C funding underwrites a launch-pad for Spirometrix to commercialize its initial product, the Fenom Pro point-of-care breathalyzer, a 1st-of-its-kind offering in asthma that comprises several sensors as well as a digital ecosystem designed to prompt evidence that may lead to enhanced clinical decision support.”

“Lately, air pollution in China has triggered public consciousness to proactively manage health, especially in regard of respiratory health and wellness. By investing in Spirometrix, we hope to empower the public with a tool that not only better diagnoses asthma, but also actively monitors and manages this chronic disease,” added Fosun Pharma chairman Chen Qiyu.

The Chinese company is no stranger to the U.S. diagnostics arena, having put $20 million into Astute Medical and its NephroCheck kidney-injury test.

Zikria said the funds will go toward finalizing the development of a hand-held breathalyzer for home use and for product launches in the U.S. and the European Union within a year.

“FeNO monitoring in the management of asthma patients at the point of care has the potential to optimize asthma therapy, improve compliance of medication use and decrease the need for emergency visits and hospitalization,” Spirometrix scientific advisor Dr. James Wolfe of Stanford University said in a press release. “It should be noted that both American Thoracic Society and European Respiratory Society have issued guidelines recommending FeNO testing for the assessment, management, and long-term monitoring of asthma.”

Filed Under: Diagnostics, Funding Roundup, Respiratory, Wall Street Beat Tagged With: Shanghai Fosun Pharmaceutical, Spirometrix

More recent news

  • Mount Sinai adopts Flosonics wearable ultrasound device
  • GE HealthCare launches next-gen intraoperative ultrasound
  • Philips launches new point-of-care ultrasound system
  • Medtronic to invest $50M in India Diabetes center
  • Corvia Medical raises $55M as it seeks FDA nod for atrial shunt

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy